On Wednesday, Starz (NASDAQ:STRZA)’s shares dwindled -2.15%, and closed at $34.55, as Starz (STRZA), declared details of the STARZ PLAY Arabia launch on April 2nd in 17 countries. The first international STARZ PLAY is a new, premium content, direct-to-consumer multiplatform subscription video service developed in conjunction with the Parsifal Entertainment Group for select markets in the Middle East and North Africa (MENA). As part of Starz’ STARZ PLAY International initiative, STARZ PLAY Arabia marks the first time that Starz has extended its flagship brand in a service offering outside of the United States.
Maaz Sheikh, former Chief Sales and Operations Officer of a leading pay TV network in MENA, is the lead executive of STARZ PLAY Arabia and serves as its President and Chief Operating Officer.
STARZ PLAY Arabia debuts in 17 countries and territories throughout the region with a particular early marketing emphasis on the Gulf Cooperation Council (GCC) countries, counting: Bahrain, Kingdom of Saudi Arabia, Kuwait, Oman, Qatar, and the United Arab Emirates. Other countries where the service is accessible comprise: Algeria, Djibouti, Egypt, Iraq, Jordan, Lebanon, Libya, Mauritania, Morocco, Palestine, and Tunisia.
Starz, through its auxiliaries, operates as a media and entertainment corporation. It operates through Starz Networks, Starz Distribution, and Starz Animation segments. The Starz Networks segment provides premium subscription video programming to U.S. multichannel video programming distributors (MVPDs), counting cable operators, satellite television providers, and telecommunications companies.
ConocoPhillips (NYSE:COP)’s shares dropped -1.49%, and settled at $64.81, during the last trading session on Wednesday, as ConocoPhillips (COP), offered details of its financial precedingities and operating plan at its Analyst and Investor Meeting in New York. Members of the corporation’s executive leadership team talk about ConocoPhillips’ aim to offer attractive annual returns to shareholders through a compelling dividend, predictable growth and a precedingity on margins and financial returns.
“The energy landscape has changed dramatically as a result of the recent decline in commodity prices, but we responded quickly to position the corporation as a core energy holding in a lower, more volatile price environment,” said Ryan Lance, chairman and chief executive officer. “We have a diverse, world-class portfolio that provides increasing capital flexibility as our major projects start to come online. We also have a strong balance sheet with the financial flexibility to respond to changes in the price environment.”
Key highlights from the meeting comprised of:
- Confirmation of the corporation’s precedingities of a compelling dividend and cash flow neutrality in 2017 and beyond.
- Cost improvement aim to reduce operating costs by $1 billion by year-end 2016 contrast with 2014. Reductions will come primarily from lower lifting costs, improvements and standardization of processes, and lower general and administrative costs.
- Details on a three-year investment plan with annual capital expenditures of about $11.5 billion. Under this plan the corporation anticipates to raise capital to development programs, primarily in the North American unconventionals, by about 50 percent as major project spending declines by about 45 percent.
- Plans for volume growth, which is predictable to be 2 to 3 percent in 2015 and raise to 1.7 million barrels of oil equivalent per day in 2017. Production from the corporation’s Asia Pacific and Middle East, Canada and Lower 48 segments is predictable to raise over this period, while production from the Alaska and Europe segments is predictable to remain relatively flat. The corporation’s growth outlook excludes production from Libya.
- Details on the corporation’s captured resource base of 44 billion barrels of oil equivalent, which are primarily low cost of supply resources in OECD countries. These resources provide a diverse source of long-term growth opportunities.
ConocoPhillips explores for, produces, transports, and markets crude oil, bitumen, natural gas, liquefied natural gas, and natural gas liquids worldwide. Its portfolio comprises shale and oil sands assets; lower-risk legacy assets in North America, Europe, Asia, and Australia; various international developments; and exploration prospects. ConocoPhillips was founded in 1917 and is headquartered in Houston, Texas.
At the end of Wednesday’s trade, LinnCo LLC (NASDAQ:LNCO)’s shares dipped -2.02%, and closed at $10.65, after LinnCo LLC (LNCO) and LINN Energy, LLC (LINE), declared that administration will host a conference call on Wednesday, April 29, 2015, at 10 a.m. Central (11 a.m. Eastern) to talk about the Corporation’s first quarter 2015 results. Prepared remarks by Mark E. Ellis, Chairman, President and Chief Executive Officer, and Kolja Rockov, Executive Vice President and Chief Financial Officer, will be followed by a question and answer session.
LinnCo, LLC, through its limited liability corporation interests in Linn Energy, LLC, focuses on the attainment and development of oil and natural gas properties in the United States. The corporation was founded in 2012 and is headquartered in Houston, Texas.
Lion Biotechnologies Inc (NASDAQ:LBIO), ended its Wednesday’s trading session with -1.98% loss, and closed at $12.39, Lion Biotechnologies Inc (LBIO), declared that data from a metastatic cervical cancer study conducted by the National Cancer Institute (NCI) was published in the Journal of Clinical Oncology in an article titled “Complete Regression of Metastatic Cervical Cancer After Treatment With Human Papillomavirus-Targeted Tumor-Infiltrating T Cells”. Data from the trial showed objective responses, counting durable, complete regressions, in patients after a single infusion of HPV-TIL.
The trial was designed to determine if the infusion of human papillomavirus tumor-infiltrating lymphocytes (HPV-TIL) could induce regression of advanced HPV-positive cancers.
“We are happy to see the results of this trial, which demonstrate potential efficacy of TIL treatment in metastatic cervical cancer, a notoriously difficult-to-treat cancer in women,” said Elma Hawkins, PhD, Lion’s president and chief executive officer. “We recently amended our CRADA with the NCI to comprise technologies based on the HPV-TIL research. With these technologies, we look forward to expanding our clinical programs and developing new treatment options for patients with cervical cancer and other solid tumors.”
Lion Biotechnologies, Inc., a clinical-stage biopharmaceutical corporation, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient’s immune system to eradicate cancer cells.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
